Morgan Stanley’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Morgan Stanley’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-128,244	Closed	-$855K	–	7940
2023 Q3	$855K	Sell	128,244 -75,466	-37%	-$627K	﹤0.01%	4891
2023 Q2	$1.85M	Buy	203,710 +50,094	+33%	+$442K	﹤0.01%	4481
2023 Q1	$1.12M	Buy	153,616 +107,946	+236%	+$801K	﹤0.01%	4796
2022 Q4	$333K	Buy	45,670 +25,747	+129%	+$191K	﹤0.01%	5440
2022 Q3	$155K	Sell	19,923 -56,754	-74%	-$482K	﹤0.01%	5853
2022 Q2	$521K	Buy	76,677 +61,942	+420%	+$474K	﹤0.01%	5398
2022 Q1	$117K	Buy	14,735 +8,830	+150%	+$56.1K	﹤0.01%	6226
2021 Q4	$33K	Buy	5,905 +2,420	+69%	+$18.2K	﹤0.01%	7003
2021 Q3	$27K	Buy	+3,485	New	+$31.8K	﹤0.01%	6982

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Morgan Stanley's PNT Position: Q4 2023 in Review

Morgan Stanley sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 128,244 shares — an estimated $855K sold.

Morgan Stanley first reported a position in PNT in Q3 2021 and held it in 9 quarters. The position peaked at $1.85M in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Morgan Stanley reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Morgan Stanley sold 128,244 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $855K.
Morgan Stanley first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Morgan Stanley's POINT Biopharma Global Inc. Common Stock position peaked at $1.85M in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.